The number of subjects in Europe is increasingly questioning the value of the market that the patient’s contribution can have for his consultations in the field of research evaluation. Various interest groups are working on it, such as Patient Focused Medicines Development (PFMD), EFPIA – European Federation of Pharmaceutical Industries and Associations, Wecan (network of patients and European lawyers in the oncology field) and the US NHC (National Health Council).
It will be necessary for industry and patients to work together to overcome the main barriers to systematic patient involvement in Pharma processes. Starting, in fact, from the definition of fair market value as provided by patients – in terms of skills and time – from a station of the contracts that regulate these partnerships. What is the fair market value for the patient’s contribution? Please read the article on @aboutpharma
